New trial data showed CagriSema led to “superior” weight loss, but at a rate much less than original expectations of 25%.

Compounding pharmacies will have to stop producing copycats of tirzepatide, the active ingredient in the blockbuster weight ...

Consumers who use telehealth or medical spas to get less expensive, compounded weight loss drugs will need to get their ...

The U.S. Food and Drug Administration said on Monday it will not take action against compounding pharmacies making copies of ...

NotCo announced Thursday the launch of its GLP Booster, a product that can be mixed into any food to naturally help you feel ...

State DHS officials say new weight-loss drugs are driving up costs for Pennsylvania’s Medicaid program, likely leading to ...

The global obsession with weight-loss drugs is reaching unprecedented levels, reshaping industries, economies, and even our ...

After Zepbound-maker Eli Lilly reduced the price of the weight-loss drug, competitor Novo Nordisk has cut the price of weight ...

Danish drugmaker Novo Nordisk said Wednesday that it will drop prices 23% for all doses of Wegovy. The new monthly price of ...

Novo Nordisk's U.S.-listed shares fell Monday morning following the release of data for a new phase 3 clinical trial of its ...

Very few people are currently being prescribed drugs for weight loss on the NHS in Scotland, research by BBC Scotland News ...

revealed data showing that its new weight-loss drug candidate showed "superior" results compared with taking nothing, but fell short of the expectations. The company said a Phase 3 trial showed ...